UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000030007 |
|---|---|
| Receipt number | R000034268 |
| Scientific Title | Phase1/2 study of Nabpaclitaxel,Gemcitabine,S1 combination therapy for unresectable pancreatic cancer |
| Date of disclosure of the study information | 2017/11/17 |
| Last modified on | 2024/03/20 13:56:33 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/11/17 01:24:39 | ||
| 2 | Update | 2018/04/16 21:27:25 | Recruitment status Anticipated trial start date |
|
| 3 | Update | 2019/05/15 11:40:58 | Date of IRB Last follow-up date |
|
| 4 | Update | 2019/05/15 11:47:50 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 5 | Update | 2019/11/19 14:22:33 | Recruitment status |
|
| 6 | Update | 2020/09/28 15:49:28 | Recruitment status |
|
| 7 | Update | 2021/03/30 21:54:10 | UMIN ID1 |
|
| 8 | Update | 2021/09/27 08:15:24 | Last follow-up date |
|
| 9 | Update | 2021/09/27 08:23:37 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Division name Last name of contact person Last name of contact person Division name Name of person sending information Name of person sending information Division name Department Email1 |
|
| 10 | Update | 2021/09/27 18:16:37 | Interventions/Control_1 Interventions/Control_1 |
|
| 11 | Update | 2022/07/08 18:40:47 | Last name of contact person Last name of contact person Division |
|
| 12 | Update | 2024/03/20 13:56:33 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Name of person sending information Name of person sending information |
